Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Transplantation and Cellular Therapy|March 6, 2026
Impact of Intensive Cyclophosphamide-containing multi-agent Bridging Therapy on Outcomes After Idecabtagene Vicleucel in Multiple MyelomaTaku Kikuchi, Ukyo Kondo, Shotaro Sugita, et al.
Ejhaem|December 1, 2025
Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving ElranatamabUkyo Kondo, Taku Kikuchi, Shotaro Sugita, et al.
Hematological Oncology|August 3, 2024
Prognostic value of the "dynamic" R2-ISS in patients with multiple myeloma undergoing anti-CD38 antibody-based triplet therapiesTaku Kikuchi, Yuki Oda, Ukyo Kondo, et al.
International Journal of Hematology|December 3, 2025
Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISSTaku Kikuchi, Shotaro Sugita, Ukyo Kondo, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|April 21, 2025
Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple MyelomaTaku Kikuchi, Miyu Watanabe, Nobuhiro Tsukada, et al.
International Journal of Hematology|July 1, 2018
Circulating tumor DNA dynamically predicts response and/or relapse in patients with hematological malignanciesSousuke Nakamura, Kazuaki Yokoyama, Nozomi Yusa, et al.
The EMBO Journal|April 24, 2012
Structural basis for Arf6-MKLP1 complex formation on the Flemming body responsible for cytokinesisHisayoshi Makyio, Minako Ohgi, Tomomi Takei, et al.
Blood|April 3, 2019
Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDSSousuke Nakamura, Kazuaki Yokoyama, Eigo Shimizu, et al.
Pageof 3